Roche is joining a big wave of companies looking to boost manufacturing in the U.S. amid trade policy coming from Washington. The biotech firm announced today it would pour $50 billion into expanding its manufacturing and research and development footprint in the country.
Currently, Roche operates 15 R&D sites and 13 manufacturing facilities. The new investments would boost those combined counts by at least four, with one of them including a 900,000-square-foot manufacturing center for Roche's weight loss medicines, with the location not yet revealed. Also, the Swiss-based firm is set to create a glucose monitoring facility in Indiana, a therapy manufacturing site in Pennsylvania, and an R&D center in Massachusetts that focuses on metabolism, cardiovascular and renal developments.
Additionally, the plans call for upgrading, expanding distribution, and manufacturing in Oregon, California, Kentucky, Arizona and Indiana.
Recommended For You
Roche forecasts that the investment, taking place over the next five years, will create more than 12,000 new jobs. This includes 1,000 with the company at its expanded and new sites, and 6,500 set aside for construction.
"Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US,” said Thomas Schinecker, CEO of Roche
“We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
The announcement by Roche comes amid tariff roll-outs and threats from the Trump administration. Already, a 10 percent flat rate that applies to most imports of foreign countries has taken effect. And recently, President Trump warned earlier this month that he would unveil a "major tariff on pharmaceuticals,” soon, as reported by CNBC.
Last month, fellow pharmaceutical giant Johnson & Johnson said it would pour $55 billion over the next four years into the country in research and development, innovation powerhouse, announced manufacturing, and technology.
"Once all new and expanded manufacturing capacity comes on-line, Roche will export more medicines from the US than it imports," Roche said.
Also, various other major tech firms have announced investments on U.S. soil this year, including Apple's $500 billion for manufacturing and training, TSMC's $100 billion for chip making, and Nvidia's hundreds of billions of dollars for manufacturing operations.
Roche noted it will unveil another site location that will be a part of its $50 billion investment soon.
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
